Glucagon-like peptide-1 (GLP-1) receptor agonist availability varies currently. Supply content is maintained regularly by DHSC.
About medicines supply advice · Advice generated by DHSC
This page was prepared and is being maintained by SPS on behalf of the Department of Health and Social Care Medicine Supply Team (DHSC).
Prescribing advice
Glucagon-like peptide-1 (GLP-1) analogues act as GLP-1 receptor agonists.
An updated Medicine Supply Notification (MSN) was issued on 18 March 2024 and the details can be viewed in the following Supply Tool post:
- Shortage of GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide)
This information supersedes the updated National Patient Safety Alert (NatPSA) on the shortage of GLP-1 receptor agonists on 3 January 2024.
The original NatPSA issued on 18 July 2023 is still available to access.
Prescribing advice is available from the following key resources listed in the NatPSA:
- Type 2 diabetes in adults: management (NICE guideline [NG28])
- Joint PCDS and ABCD guidance: GLP-1 receptor agonist national shortage
- Obesity: identification, assessment and management (NICE clinical guideline [CG189])
Dulaglutide
Limited availability
The following dulaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Trulicity 0.75 mg solution for injection in pre-filled pen
- Trulicity 1.5 mg solution for injection in pre-filled pen
- Trulicity 3 mg solution for injection in pre-filled pen
- Trulicity 4.5 mg solution for injection in pre-filled pen
Affected
The following active supply issues exist:
- Shortage of Dulaglutide (Trulicity) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection devices
Exenatide
Available
The following exenatide products are available but are unable to support uplift in demand from other GLP-1 receptor agonists:
- Byetta 5micrograms/0.02mL solution for injection 1.2mL pre-filled pens
- Bydureon 2mg/0.85mL prolonged-release suspension for injection 1.2mL pre-filled pens
Affected
The following active supply issues exist:
- Archived: Discontinuation of Exenatide (Byetta) 5microgram/0.02ml and 10microgram/0.04ml solution for injection
Liraglutide
Limited availability
The following injectable liraglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Victoza 6mg/mL solution for injection in prefilled pen
- Saxenda 6mg/mL solution for injection in prefilled pen
Affected
The following active supply issues exist:
- Shortage of Liraglutide (Victoza) 6mg/ml solution for injection
- Shortage of Liraglutide (Saxenda) 6mg/ml solution for injection 3ml pre-filled disposable devices
Semaglutide injection
Limited availability
The following injectable semaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Ozempic 0.25mg solution for injection in pre-filled pen
- Ozempic 1mg solution for injection in pre-filled pen
Available
Wegovy (semaglutide) is now available in the following presentations by Novo Nordisk:
- Wegovy 0.25mg FlexTouch solution for injection in pre-filled pen
- Wegovy 0.5mg FlexTouch solution for injection in pre-filled pen
- Wegovy 1mg FlexTouch solution for injection in pre-filled pen
- Wegovy 1.7mg FlexTouch solution for injection in pre-filled pen
- Wegovy 2.4mg FlexTouch solution for injection in pre-filled pen
Accessing Wegovy for weight loss: Everything you need to know contains further information regarding access on the NHS.
Affected
The following active supply issues exist:
- Ozempic 0.5mg solution for injection in pre-filled pen
Shortage of Semaglutide (Ozempic) solution for injections contains further information.
Semaglutide tablets
Available
Rybelsus tablets are now available in sufficient quantities to support initiation of GLP-1 receptor agonist treatment in people with type 2 diabetes (T2DM):
- Rybelsus 3mg tablets
- Rybelsus 7mg tablets
- Rybelsus 14mg tablets
Further advice
Prescribing available GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) receptor agonist availability varies currently. Supply content is maintained regularly by DHSC.
Medicines Supply Tool
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.
Update history
- Updated to reflect publication of the MSN on 18 March 2024.
- Ozempic 0.5mg solution for injection in pre-filled pen is out of stock.
- Rybelsus supply position clarified.
- Link to the updated NatPSA published 3 Jan 2024; link to NG28 updated and link to CG189 has been added.
- Shortage of Byetta 10micrograms/0.04mL solution for injection 1.2mL pre-filled pens added.
- Product details and link to further information added for Wegovy. Status changed from intermittent to limited availability for other GLP-1 RAs.
- Content updated to reflect the publication of the NatPSA and Saxenda supply issue added.
- Bydureon has been added to the exenatide section.
Show all history Show less history
.webp)
